Full-Time

Business Manager

Confirmed live in the last 24 hours

HeartFlow

HeartFlow

501-1,000 employees

Non-invasive cardiac testing for heart disease

Compensation Overview

$240k - $280k/yr

+ Stock Options + Benefits Package

Senior

Washington, USA + 2 more

More locations: Oregon, USA | California, USA

Candidates must be based in California, Washington, or Oregon.

Category
Customer Success
Sales & Account Management
Required Skills
Sales
Requirements
  • Meeting Sales Goals
  • Motivation for Sales team
  • Territory Management
  • Presentation Skills
  • Performance Management
  • Building Relationships
  • Emphasizing Excellence
  • Negotiation
  • Results Driven
  • Sales Planning
  • Managing Profitability
  • Demonstrate ability to hire, develop, performance manage and promote talent
  • Proven sales management skills and track-record of sales achievement
  • Account development - Experience building and supporting strong clinical programs
  • Clinical / technical proficiency - Quick learner able to grasp new clinical/technical information and then disseminate to customers
  • Develop relationships with key account stakeholders, drive awareness of a cCTA/FFRct pathway, broaden Heartflow referrals, and deepen Heartflow adoption
  • Work in a cross functional capacity to coordinate field and HQ resources needed to support focused customers and execute program development plans, support sales, marketing, education and training
  • Customer-focused mentality
  • Self-motivated and ability to initiate, organize, and complete projects
  • Excellent problem-solving ability, especially under pressure
  • Extremely strong work ethic
  • Works well in a cross-functional team environment
  • Excellent verbal and written communication skills. Professional etiquette
  • Experience with Salesforce.com or similar CRM
Responsibilities
  • Will work cross functionally to create solutions as new opportunities present
  • Create progressive programming that disrupts the traditional means to reach ordering physicians who treat and manage patients with CAD
  • Will work directly with key strategic Heartflow accounts to drive growth and adoption of a cCTA and FFRct clinical pathway
  • Facilitate cross-functional collaboration throughout the organization
  • Increase Heartflow usage within the designated key strategic Heartflow account by maintaining and building relationships with referring physicians and other key clinical stakeholders
  • Educating customers on Heartflow’s value proposition by giving presentations/ having discussions with referring MDs
  • Promoting / championing Heartflow and building advocacy
  • Production/Success/Achievement of the Territory Account Manager will be evaluated and based on performance in active/targeted accounts (metrics)
Desired Qualifications
  • Knowledge of cardiac patient pathways and diagnostic technology is preferred
  • Degree in Science, Medical, Business, Marketing or Technical field is preferred
  • Prior experience in medical device, cardiology pharmaceuticals, cardiology radio-pharmaceuticals, hospital, or medical software is highly desired
  • Experience with introducing new cardiovascular technologies into hospitals is highly desired

HeartFlow provides a non-invasive cardiac test that helps visualize a patient's coronary arteries in detail. This technology allows physicians to create more effective treatment plans for heart disease, making cardiovascular care safer and more efficient. Unlike traditional methods that may require invasive procedures, HeartFlow's approach reduces risks for patients and lowers costs for healthcare providers. The company's main product, the HeartFlow Analysis, includes various analyses such as FFRCT Analysis and Plaque Analysis, and has received FDA clearance for use in the United States, as well as approvals in the UK, Japan, and Canada. HeartFlow differentiates itself from competitors by focusing on non-invasive diagnostics and offering a comprehensive suite of tools for heart disease management. The company's goal is to improve the diagnosis and treatment of heart disease, ultimately enhancing patient care.

Company Size

501-1,000

Company Stage

Debt Financing

Total Funding

$1B

Headquarters

Redwood City, California

Founded

2010

Simplify Jobs

Simplify's Take

What believers are saying

  • HeartFlow's technology aligns with the growing trend of AI adoption in healthcare.
  • The global non-invasive cardiac imaging market is projected to grow significantly, benefiting HeartFlow.
  • Updated AHA guidelines emphasize non-invasive testing, increasing demand for HeartFlow's FFRCT Analysis.

What critics are saying

  • Emerging AI-driven cardiovascular tools could threaten HeartFlow's market share.
  • HeartFlow's reliance on continuous funding rounds indicates potential financial instability.
  • New regulatory requirements for AI in healthcare could necessitate costly adjustments for HeartFlow.

What makes HeartFlow unique

  • HeartFlow offers a unique AI-driven non-invasive cardiac test for coronary artery visualization.
  • The company's technology integrates over two decades of scientific evidence with AI advancements.
  • HeartFlow is the only provider offering both anatomical and physiological coronary artery visualization.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Stock Options

401(k) Company Match

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

-2%
Intelligence360
Apr 22nd, 2025
HeartFlow Raises $50M in Debt Financing

HeartFlow has filed a notice for an exempt offering of securities to raise $50 million in new debt financing. This filing with the U.S. Securities and Exchange Commission is required under federal securities law for companies selling securities without registration under the Securities Act of 1933, specifically under Rule 504 or 506 of Regulation D or Section 4(a)(5). The notice must be filed within 15 days after the first sale of securities in the offering.

Benzinga
Mar 26th, 2025
Heartflow Secures $98M in Funding

Heartflow, Inc. announced a $98 million convertible notes financing led by its parent company, Heartflow Holding, Inc. New and existing investors, including Fidelity Management, Janus Henderson, and Bain Capital, participated. The funds will support R&D to advance Heartflow's AI-driven coronary care platform. Heartflow's technology, recognized for innovation, aims to improve CAD diagnosis and management. The platform has been used for over 400,000 patients globally.

National Law Review
Mar 26th, 2025
Heartflow Closes $98 Million Convertible Notes Financing

Heartflow was recently named one of Fast Company's Most Innovative Companies in Medical Devices for 2025 and won the Innovation in Cardiac Imaging award at the Global Cardiovascular Awards 2025.

Hit Consultant
Jan 22nd, 2025
Heartflow And Boone Heart Institute Launch Gamefilm Registry To Study Heart Health In Retired Nfl Players

HeartFlow and Boone Heart Institute Launch GAMEFILM Registry to Study Heart Health in Retired NFL Players. by Fred Pennic 01/22/2025 Leave a Comment. What You Should Know: – HeartFlow, a global leader in AI-driven heart care solutions, and Boone Heart Institute, a renowned cardiovascular care provider in Denver, today announced the launch of the GAMEFILM Registry. – GAMEFILM Registry will utilize advanced imaging and AI technology to assess and better understand coronary artery disease (CAD) risk in retired National Football League (NFL) players.Understanding the Unique Cardiovascular Risks of Retired NFL PlayersCardiovascular disease remains the leading cause of death globally. Despite advancements in diagnostics, many heart attacks and strokes occur in individuals without prior symptoms. Early identification of high-risk individuals is critical for effective prevention and treatment. Retired NFL players often face unique cardiovascular health challenges due to the intense physical demands of their careers

GlobeNewswire
Oct 18th, 2024
HeartFlow Announces New Category I CPT Code from the American Medical Association for AI-Enabled Plaque Analysis to Assess Risk for Coronary Artery Disease

HeartFlow announces new Category I CPT code from the American Medical Association for ai-enabled Plaque Analysis to assess risk for coronary artery disease.